Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry

Huang, Tzu Chuan; Huang, Shang Yi; Yao, Ming; Lin, Chen; Hwang, Wen Li; Gau, Jyh Pyng; Tan, Tran-Der; Wang, Po Nan; Liu, Yi Chang; Lin, Shih Chiang; Kao, Ruey Ho; Pei, Sung Nan; Yu, Ming; Lin, Hung‐Hsuan; Su, Yung Cheng; Chen, Chih‐Cheng; Li, Sin-Syue; Wu, Yi-Ying

doi:10.1016/j.jfma.2018.07.020

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current literature five articles were found in which the changes of immunological parameters in female and male patients with MM after autologous HSCT were analysed [8,[29][30][31][32] and only one after allogeneic transplantation [26]. The authors investigated changes in the immune system at various stages of the disease, including less parameters than in the current study, and they presented the results for the whole studied population irrespective of gender.…”

Section: The Immune Reconstitutionmentioning

confidence: 99%

Gender and the length of time since autologous hematopoietic stem cell transplantation—What is their influence on the immune reconstitution in multiple myeloma patients?

Popierz-Rydlewska,

Merkiel-Pawłowska,

Łojko-Dankowska

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Introduction In the literature there is lack of information on the influence of gender and time since autologous hematopoietic stem cell transplantation (HSCT) on the immune reconstitution in multiple myeloma (MM) patients. Objective The aim of this study was to assess the diversity of the immune reconstitution according to gender in MM patients after autologous HSCT on the day of the clinic discharge and on the 29th day after discharge, as well as to investigate the changes in the immune system in females and males after staying at home for 28 days. Method The studied population comprised 13 females and 13 males after autologous HSCT. On the day of the clinic discharge and on the 29th day after discharge blood samples were taken to analyse 22 immunological parameters. Statistical analysis was performed using STATISTICA 10 StatSoft Poland. For multiple comparisons, the Bonferroni correction was used. Results No statistically significant differences were observed in the analysed immunological parameters between the studied females and males with MM on the day of the clinic discharge and on the 29th day after discharge. However, on the 29th day after the clinic discharge compared to the day of the clinic discharge, statistically significant differences were found in 8 immunological parameters among females and 6 immunological parameters among males. Conclusion and recommendation Our results indicate that the immune reconstitution is similar but not the same in patients of both genders. Statistically significant differences in the immune response in the studied females and males imply that gender may play a role in the immune reconstitution and that the results obtained in MM patients should be analysed separately in females and males. In order to explain the observed changes in the immune system according to gender, further research should be carried out on a larger population. This would most probably make it possible to find their clinical application.

show abstract

Section: The Immune Reconstitutionmentioning

confidence: 99%

Gender and the length of time since autologous hematopoietic stem cell transplantation—What is their influence on the immune reconstitution in multiple myeloma patients?

Popierz-Rydlewska,

Merkiel-Pawłowska,

Łojko-Dankowska

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Huang et al [ 49 ] analyzed data on 396 patients with MM in the TBMTR database who underwent auto-HSCT from 2006 to 2015 to determine treatment efficacy and identify prognostic factors. In this transplant cohort, 61.9%, 23.7%, and 14.4% of the patients had Durie–Salmon disease stages III, II, and I, respectively.…”

Section: S Pecial Hematopoietic Stem Cell Transplantation A...mentioning

confidence: 99%

Recent advancements in hematopoietic stem cell transplantation in Taiwan

Li,

Tsai,

Huang

et al. 2024

Tzu Chi Medical Journal

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone’s experience and promote the advances of HSCT in Taiwan to gather everyone’s experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival. In Taiwan, transplant donors showed remarkable growth from unrelated (24.8%) and haploidentical (10.5%) donors. The number of older patients (17.4%; aged ≥61 years) who underwent transplantation has increased markedly. This review summarizes several significant developments in HSCT treatment in Taiwan. First, the use of Anti-thymocyte globulin (ATG) and intravenous busulfan regimens were important risk factors for predicting hepatic sinusoidal obstruction syndrome. Second, a new, machine learning-based risk prediction scoring system for posttransplantation lymphoproliferative disorder has identified five risk factors: aplastic anemia, partially mismatched related donors, fludarabine use, ATG use, and acute skin graft-versus-host disease. Third, although the incidence of idiopathic pneumonia syndrome was low (1.1%), its mortality rate was high (58.1%). Fourth, difficult-to-treat mantle cell and T-cell lymphomas treated with autologous HSCT during earlier remission had higher survival rates. Fifth, treatment of incurable multiple myeloma with autologous HSCT showed a median progression-free survival and overall survival of 46.5 and 70.4 months, respectively. Sixth, different haploidentical transplantation strategies were compared. Seventh, caution should be taken in administering allogeneic HSCT treatment in older patients with myeloid leukemia with a Charlson Comorbidity Index ≥3 because of a higher risk of nonrelapse mortality.

show abstract

Báo cáo các trường hợp bệnh nhân đa u tủy xương được ghép tế bào gốc tạo máu tự thân tại Bệnh viện Trung ương Huế

Tôn Thất

2024

jcmhch

View full text Add to dashboard Cite

Tóm tắt Mục tiêu: Đánh giá bước đầu tính khả thi và hiệu quả trong quá trình ghép tế bào gốc tự thân trên bệnh nhân đa u tủy xương. Đối tượng, phương pháp: 4 bệnh nhân đa u tủy xương được điều trị 4 chu kỳ theo phác đồ VTD (Velcade, Thalidomid, Dexamethasone) sau đó hóa trị liều cao với melphalan và ghép tế bào gốc tạo máu tự thân. Phương pháp nghiên cứu: mô tả hàng loạt trường hợp. Kết quả: 04 bệnh nhân có độ tuổi từ 54 - 61 tuổi, đều thuộc nhóm đa u tủy xương thể IgG, có nguy cơ trung bình - cao, giai đoạn II - III. Sau 4 đợt điều trị với phác đồ VTD có 1/4 bệnh nhân đạt lui bệnh một phần, 3/4 bệnh nhân đạt lui bệnh một phần rất tốt. Thể tích túi tế bào gốc thu được trung bình là 722 ± 53,2ml. Liều tế bào gốc CD34+ truyền cho bệnh nhân trung bình là 8,0 ± 2,8 (x106/kg). Thời gian hồi phục bạch cầu trung tính trung bình là 11,3 ± 1,3 ngày, trong đó số lượng bạch cầu trung tính giảm thấp nhất trung bình là 0,02 ± 0,01 G/L. Thời gian hồi phục tiểu cầu trung bình là 10 ± 1,6 ngày; trong đó số lượng tiểu cầu giảm thấp nhất trung bình là 19,5 ± 9,7 G/L. Thời gian sử dụng G-CSF trung bình là 7,8 ± 1,3. Cả 04 bệnh nhân đều cần truyền tiểu cầu trong quá trình điều trị sau ghép. 4/4 bệnh nhân đều sử dụng thuốc eltrombopag. Thời gian cách ly trung bình là 14 ± 2,2 ngày, ngắn nhất là 11 ngày, dài nhất là 15 ngày. Biến chứng gặp nhiều nhất ở bệnh nhân trong quá trình ghép là buồn nôn, nôn (4/4), tiêu chảy (3/4) và sốt giảm bạch cầu trung tính (3/4). Cả 04 bệnh nhân đều có sử dụng kháng sinh tĩnh mạch, một bệnh nhân cần dùng thuốc kháng nấm trong 12 ngày. Đánh giá sau ghép tế bào gốc tạo máu tự thân 3 tháng, tất cả bệnh nhân trong nghiên cứu đều đạt lui bệnh hoàn toàn. Kết luận: Phác đồ VTD phối hợp với melphalan liều cao và ghép tế bào gốc tạo máu tự thân là tương đối an toàn và bước đầu cho thấy hiệu quả tốt trong điều trị bệnh đa u tủy xương. REPORT ON AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS AT HUE CENTRAL HOSPITAL Objective: Initial assessment of the feasibility and effectiveness of autologous stem cell transplantation in multiple myeloma patients Methods: Descriptive case series. Four multiple myeloma patients were treated with 4 cycles of VTD regimen (Velcade, Thalidomid, Dexamethasone) followed by high - dose chemotherapy with melphalan and autologous hematopoietic stem cell transplantation. Results: Four patients were in the age group of 54 - 61, classified as IgG subtype, with medium to high risk, in stages II - III. One - quarter achieved partial remission, while three - quarters achieved very good partial remission. The average volume of harvested stem cells was 722 ± 53.2ml. The average CD34+ stem cell dose infused was 8.0 ± 2.8 (x106/kg). The median time to neutrophil engraftment was 11.3 ± 1.3 days, with the lowest neutrophil count: 0.02 ± 0.01 G/L. The median time to platelet engraftment was 10 ± 1.6 days, with the lowest platelet count: 19.5 ± 9.7 G/L. The average duration of G-CSF usage was 7.8 ± 1.3 days. All four patients required platelet transfusions were under posttransplant. All patients received eltrombopag. The average isolation period was 14 ± 2.2 days, ranging from 11 to 15 days. The most common complications during transplantation were nausea, vomiting (4/4), diarrhea (3/4), and febrile neutropenia (3/4). All four patients used intravenous antibiotics, one patient was required with antifungal treatment for 12 days. Evaluation after 3 months of autologous hematopoietic stem cell transplantation, all patients in the stydy achieved complete remission. Conclusion: The VTD regimen combined with high dose melphalan and autologous hematopoietic stem cell transplantation is relatively safe and initially shows good effectiveness in the treatment of multiple myeloma.

show abstract

Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry

Abstract: In conclusion, our cohort showed that myeloma patients with early DSS and better treatment response before ASCT had better long-term survival outcomes.

Cited by 3 publications

References 32 publications

Gender and the length of time since autologous hematopoietic stem cell transplantation—What is their influence on the immune reconstitution in multiple myeloma patients?

Gender and the length of time since autologous hematopoietic stem cell transplantation—What is their influence on the immune reconstitution in multiple myeloma patients?

Recent advancements in hematopoietic stem cell transplantation in Taiwan

Báo cáo các trường hợp bệnh nhân đa u tủy xương được ghép tế bào gốc tạo máu tự thân tại Bệnh viện Trung ương Huế

Contact Info

Product

Resources

About